在近日举行的BioChina大会上，XDC（偶联药物）作为肿瘤治疗的前沿领域备受瞩目。同宜医药创始人、CEO黄保华博士受邀出席专家嘉宾访谈，深入剖析了XDC赛道的差异化竞争策略。黄博士指出，XDC是真正具备“源头创新”属性的领域，行业同仁应如“八仙过海”各显神通，利用自身技术特点开发出能够“改变临床实践（Practice Changing）甚至具备治愈潜力（Curative）”的药物。
Pamplona Therapeutics and Coherent Biopharma today announced a strategic collaboration to combine Pamplona’s AI-driven targeted...
日前，同宜医药（苏州）有限公司与南京科络思生物科技有限公司在南京科络思生物总部签署全面战略合作协议。
同宜医药宣布已与 MultiValent Biotherapies, Inc.（以下简称“MultiValent”）就治疗前列腺癌的多肽类偶联药物 CBP-1018 达成独家许可协议。
Suzhou, China, February 21, 2025 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration...
October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention
The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...
Recently, Coherent Biopharma disclosed the latest preclinical research progress of CBP-8008, at the 2024 American Association...